Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials


NMDAR Modulation As a Therapeutic Target and Probe of Neural Dysfunction in OCD


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT02624596

Organisation Name: Stanford University

Overal Status: Recruiting

Start Date: June 2016

Last Update: July 23, 2020

Lead Sponsor: Stanford University

Brief Summary: The purpose of this study is to understand how ketamine brings about rapid improvement in Obsessive-Compulsive Disorder (OCD) symptoms.

Conditions:
  • Obsessive-Compulsive Disorder


Total execution time in seconds: 0.15361905097961